Mesityl Oxide

CAS RN:141-79-7

Health Effects

0.2.1 SUMMARY OF EXPOSURE
  • 0.2.1.1 ACUTE EXPOSURE
    • A) Mesityl oxide has the potential to produce narcosis, liver and kidney damage, and CNS toxicity such as ataxia, seizures, headache, and vertigo.
    • B) It is an eye and mucous membrane irritant. It can cause opaque cornea, keratoconus, and extensive necrosis of cornea.
    • C) Brief skin exposure may produce irritation, and prolonged or repeated contact may result in dermatitis. It is readily absorbed through intact skin.
    • D) Mesityl oxide is toxic by ingestion, inhalation, dermal and intraperitoneal routes.
  • 0.2.1.2 CHRONIC EXPOSURE
    • A) Prolonged exposure can injure the liver, kidneys and lungs.
    • B) Prolonged or repeated skin exposure may result in dermatitis.
0.2.3 VITAL SIGNS0.2.4 HEENT
  • 0.2.4.1 ACUTE EXPOSURE
    • A) Eye irritation was seen at 25 ppm and is expected at 100 ppm.
    • B) Nasal irritation was seen in humans at 50 ppm. The compound is definitely irritating at 200 ppm.
0.2.6 RESPIRATORY
  • 0.2.6.1 ACUTE EXPOSURE
    • A) Dyspnea is expected at 100 ppm.
0.2.7 NEUROLOGIC
  • 0.2.7.1 ACUTE EXPOSURE
    • A) Vertigo and headache is expected at 100 ppm. Experimental animals have experienced narcosis, ataxia, and seizures.
0.2.8 GASTROINTESTINAL
  • 0.2.8.1 ACUTE EXPOSURE
    • A) 50 ppm produces an unpleasant taste which may remain for 3 to 6 hours postexposure.
0.2.14 DERMATOLOGIC
  • 0.2.14.1 ACUTE EXPOSURE
    • A) Dermatitis has been seen after sustained skin contact with the liquid.
0.2.21 CARCINOGENICITY
  • 0.2.21.1 IARC CATEGORY
    • A) IARC Carcinogenicity Ratings for CAS141-79-7 (International Agency for Research on Cancer (IARC), 2016; International Agency for Research on Cancer, 2015; IARC Working Group on the Evaluation of Carcinogenic Risks to Humans, 2010; IARC Working Group on the Evaluation of Carcinogenic Risks to Humans, 2010a; IARC Working Group on the Evaluation of Carcinogenic Risks to Humans, 2008; IARC Working Group on the Evaluation of Carcinogenic Risks to Humans, 2007; IARC Working Group on the Evaluation of Carcinogenic Risks to Humans, 2006; IARC, 2004):
      • 1) Not Listed
Find more information on this substance at: Hazardous Substances Data Bank , TOXNET , PubMed